Cargando…

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report

BACKGROUND: Patients with ovarian clear cell carcinoma (OCCC) have a poor prognosis because they show low sensitivity to platinum-based chemotherapy. New treatments for refractory OCCC are urgently needed. CASE PRESENTATION: We present a patient with refractory OCCC in whom conventional chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yu-Chien, Wen, Kuo-Chang, Sung, Pi-Lin, Chou, Yu-Ting, Liew, Phui-Ly, Chen, Lin-Yu, Huang, Rui-Lan, Lai, Hung-Cheng, Chang, Lu-Te
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725117/ https://www.ncbi.nlm.nih.gov/pubmed/33292376 http://dx.doi.org/10.1186/s13048-020-00751-3

Ejemplares similares

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
por: Zibetti Dal Molin, Graziela, et al.
Publicado: (2018)

Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report
por: Zhao, Yingchao, et al.
Publicado: (2022)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer
por: Defferrari, Carlotta, et al.
Publicado: (2012)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
por: Liu, Xiu, et al.
Publicado: (2023)

DEF6 expression in ovarian carcinoma correlates with poor patient survival
por: Liew, Phui-Ly, et al.
Publicado: (2016)

Epigenomic Analysis Reveals the KCNK9 Potassium Channel as a Potential Therapeutic Target for Adenomyosis
por: Chu, Ling-Hui, et al.
Publicado: (2022)

ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma
por: Sato, Emi, et al.
Publicado: (2018)

Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression
por: Choi, Jae Yoon, et al.
Publicado: (2017)

Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
por: Takahashi, Kazuaki, et al.
Publicado: (2021)

Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors
por: Liew, Phui‐Ly, et al.
Publicado: (2018)

Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
por: Choi, Min Chul, et al.
Publicado: (2020)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
por: Maeda, Daichi, et al.
Publicado: (2010)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma
por: Kao, Chien-Hsiang, et al.
Publicado: (2022)

Angiostrongylus cantonensis causes cognitive impairments in heavily infected BALB/c and C57BL/6 mice
por: Jhan, Kai-Yuan, et al.
Publicado: (2020)

ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
por: Berns, Katrien, et al.
Publicado: (2018)

Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction
por: Chang, Shih-Ching, et al.
Publicado: (2020)

Necrotizing Fasciitis in a Patient with Metastatic Clear Cell Ovarian Carcinoma Treated with Bevacizumab
por: Haider, Asim, et al.
Publicado: (2022)

Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan
por: Chen, Wei-Chun, et al.
Publicado: (2017)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model
por: Ishikura, Nobuyuki, et al.
Publicado: (2019)

BHLHE22 Expression Is Associated with a Proinflammatory Immune Microenvironment and Confers a Favorable Prognosis in Endometrial Cancer
por: Darmawi,, et al.
Publicado: (2022)

Novel heavily fucosylated glycans as a promising therapeutic target in colorectal cancer
por: Tsai, Kuei-Yen, et al.
Publicado: (2023)

Bevacizumab helped resolve pericardial and pleural effusion that was associated with malignant ovarian clear cell carcinoma
por: Ueda, Tomoko, et al.
Publicado: (2016)

The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects
por: Mao, Chih-Lin, et al.
Publicado: (2022)

Case report: Local cryoablation combined with pembrolizumab to eliminate lung metastases from ovarian clear cell carcinoma
por: Meng, Liangliang, et al.
Publicado: (2022)

EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers
por: Alldredge, Jill K., et al.
Publicado: (2017)

CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma
por: Kawahara, Naoki, et al.
Publicado: (2021)

Immune checkpoint inhibitors combined with chemotherapy/bevacizumab therapy for patients with advanced lung cancer and heavily treated with EGFR mutation: a retrospective analysis
por: Hu, Ran, et al.
Publicado: (2021)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy
por: Marcrom, Samuel, et al.
Publicado: (2017)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
por: Tate, Shinichi, et al.
Publicado: (2021)

The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis
por: Su, Kuo-Min, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_to7c4iv20547kgqtm0tev9ds6b